Intraperitoneal insulin infusion: on the way to the artificial pancreas

Creating an "artificial pancreas" (a "closed loop" insulin pump, with self-adjusting insulin abilities, based on real time continuous glucose monitoring data) – is one of the most actual medical challenges of modern engineering and cybernetics.Artificial pancreas (AP) prototypes...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Vladimir Aleksandrovich Karpel'ev, Elena Anatol'evna Fedorova, Yury Ivanovich Philippov, Aleksandr Yur'evich Mayorov, Marina Vladimirovna Shestakova
Formato: article
Lenguaje:EN
RU
Publicado: Endocrinology Research Centre 2015
Materias:
Acceso en línea:https://doaj.org/article/de55be4fd4da4e3eb7b2354f0b78b6a6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:de55be4fd4da4e3eb7b2354f0b78b6a6
record_format dspace
spelling oai:doaj.org-article:de55be4fd4da4e3eb7b2354f0b78b6a62021-11-14T09:00:19ZIntraperitoneal insulin infusion: on the way to the artificial pancreas2072-03512072-037810.14341/DM2015332-45https://doaj.org/article/de55be4fd4da4e3eb7b2354f0b78b6a62015-10-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7228https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Creating an "artificial pancreas" (a "closed loop" insulin pump, with self-adjusting insulin abilities, based on real time continuous glucose monitoring data) – is one of the most actual medical challenges of modern engineering and cybernetics.Artificial pancreas (AP) prototypes based on wearable insulin pump with subcutaneous insulin delivery are still problematic, mainly because of slow insulin pharmacokinetics. Intravenous insulin infusion via AP allows effectively maintain euglycaemia for inpatients, due to insulin pharmacokinetics and pharmacodynamics advantages. Unfortunately, it can’t be used for outpatients. Intraperitoneal insulin infusion is still relatively infrequently used in the world, but it is a promising alternative, compared to both previous methods due to a physiological action profile, fast insulin pharmacokinetics, relatively better safety and availability for outpatient usage.The purpose of this review is to describe the intraperitoneal insulin infusion features for diabetes patients at a point of AP creation perspectives.Vladimir Aleksandrovich Karpel'evElena Anatol'evna FedorovaYury Ivanovich PhilippovAleksandr Yur'evich MayorovMarina Vladimirovna ShestakovaEndocrinology Research Centrearticleinsulin pumpinsulinpharmacokineticsintraperitoneal infusiondiabetes mellitusartificial pancreasNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 18, Iss 3, Pp 32-45 (2015)
institution DOAJ
collection DOAJ
language EN
RU
topic insulin pump
insulin
pharmacokinetics
intraperitoneal infusion
diabetes mellitus
artificial pancreas
Nutritional diseases. Deficiency diseases
RC620-627
spellingShingle insulin pump
insulin
pharmacokinetics
intraperitoneal infusion
diabetes mellitus
artificial pancreas
Nutritional diseases. Deficiency diseases
RC620-627
Vladimir Aleksandrovich Karpel'ev
Elena Anatol'evna Fedorova
Yury Ivanovich Philippov
Aleksandr Yur'evich Mayorov
Marina Vladimirovna Shestakova
Intraperitoneal insulin infusion: on the way to the artificial pancreas
description Creating an "artificial pancreas" (a "closed loop" insulin pump, with self-adjusting insulin abilities, based on real time continuous glucose monitoring data) – is one of the most actual medical challenges of modern engineering and cybernetics.Artificial pancreas (AP) prototypes based on wearable insulin pump with subcutaneous insulin delivery are still problematic, mainly because of slow insulin pharmacokinetics. Intravenous insulin infusion via AP allows effectively maintain euglycaemia for inpatients, due to insulin pharmacokinetics and pharmacodynamics advantages. Unfortunately, it can’t be used for outpatients. Intraperitoneal insulin infusion is still relatively infrequently used in the world, but it is a promising alternative, compared to both previous methods due to a physiological action profile, fast insulin pharmacokinetics, relatively better safety and availability for outpatient usage.The purpose of this review is to describe the intraperitoneal insulin infusion features for diabetes patients at a point of AP creation perspectives.
format article
author Vladimir Aleksandrovich Karpel'ev
Elena Anatol'evna Fedorova
Yury Ivanovich Philippov
Aleksandr Yur'evich Mayorov
Marina Vladimirovna Shestakova
author_facet Vladimir Aleksandrovich Karpel'ev
Elena Anatol'evna Fedorova
Yury Ivanovich Philippov
Aleksandr Yur'evich Mayorov
Marina Vladimirovna Shestakova
author_sort Vladimir Aleksandrovich Karpel'ev
title Intraperitoneal insulin infusion: on the way to the artificial pancreas
title_short Intraperitoneal insulin infusion: on the way to the artificial pancreas
title_full Intraperitoneal insulin infusion: on the way to the artificial pancreas
title_fullStr Intraperitoneal insulin infusion: on the way to the artificial pancreas
title_full_unstemmed Intraperitoneal insulin infusion: on the way to the artificial pancreas
title_sort intraperitoneal insulin infusion: on the way to the artificial pancreas
publisher Endocrinology Research Centre
publishDate 2015
url https://doaj.org/article/de55be4fd4da4e3eb7b2354f0b78b6a6
work_keys_str_mv AT vladimiraleksandrovichkarpelev intraperitonealinsulininfusiononthewaytotheartificialpancreas
AT elenaanatolevnafedorova intraperitonealinsulininfusiononthewaytotheartificialpancreas
AT yuryivanovichphilippov intraperitonealinsulininfusiononthewaytotheartificialpancreas
AT aleksandryurevichmayorov intraperitonealinsulininfusiononthewaytotheartificialpancreas
AT marinavladimirovnashestakova intraperitonealinsulininfusiononthewaytotheartificialpancreas
_version_ 1718429559420878848